Ex-Pfiz­er CEO's start­up Cen­trex­ion gets $67M for PhI­II painkiller

Cen­trex­ion Ther­a­peu­tics, a Boston-based start­up led by ex-Pfiz­er CEO Jeff Kindler, just raised $67 mil­lion to bring its painkiller drug in­to Phase III tri­als. If it works, the treat­ment should ap­pease reg­u­la­tors con­cerned with ad­dic­tion prob­lems, as the drug is a non-opi­oid and non-steroid way to treat pain.

“I be­lieve the opi­oid cri­sis is a prod­uct of a pain cri­sis,” Kindler tells me. “Non-ad­dic­tive, non-steroidal al­ter­na­tives to opi­oids are an enor­mous need.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER